Prognosis of metastatic colorectal cancer has dramatically improved during these two last decades, through a better understanding of therapeutic goals and the development of news drugs such as biologics. The character resectable, potentially resectable or not resectable of colorectal cancer liver metastasis should be considered at baseline because it determines the systemic chemotherapy which will be conducted. Considering resectable metastasis, 6 courses of FOLFOX (5 fluoro-uracil + oxaliplatin) will be administered before and after surgery in the goal of "cleaning" the body from the potential micrometastasis. In potentially resectable liver metastasis, the objective of the chemotherapy will be to get a tumor shrinkage, enabling microscopically complete resection while leaving enough functional hepatic parenchyma. In case of unresectable metastasis, obtaining a tumor response with an intensive induction chemotherapy is the guarantee of a good disease control, and authorizes to light treatment during a maintenance period, or a therapeutic break in selected patients, without altering the prognosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Correlation Between Postoperative Complications and Number of Colorectal Liver Metastases Resected.
J Surg Res
January 2025
Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa. Electronic address:
Introduction: This study aimed to describe the relationship between the number of colorectal liver metastases (CRLM) resected and the rate of postoperative complications and to determine a threshold level, if any, for which the risk of postoperative complications outweighs the benefit of resection of metastatic disease.
Methods: This is a retrospective analysis of the American College of Surgeons National Surgical Quality Improvement Program database from 2019 to 2021. Patients were divided into three major groups: one to two, three to four, and more than five CRLM.
"Evaluating Current Diagnostic and Treatment Challenges in Colorectal Cancer: Strategies for improving care and outcomes in Georgia".
Cancer Treat Res Commun
January 2025
Caucasus Medical Centre, Tbilisi, Georgia; Ilia State University- School of Medicine. Tbilisi, Georgia. Electronic address:
Purpose: An initial analysis of population-based cancer survival data from Georgia revealed lower CRC survival rates compared to high-income countries. We conducted the study to address this issue and propose strategies for enhancing CRC care.
Patients And Methods: We analyzed CRC statistics, reviewed screening programs, and examined published CRC research in Georgia.
Clinical implications of DNA ploidy, stroma, and nucleotyping in predicting peritoneal metastasis risk for gastric cancer.
BMC Cancer
January 2025
Department of Gastrointestinal Surgery I Section, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Background: Gastric cancer peritoneal metastasis lacks effective predictive indices. This article retrospectively explored predictive values of DNA ploidy, stroma, and nucleotyping in gastric cancer peritoneal metastasis.
Methods: A comprehensive analysis was conducted on specimens obtained from 80 gastric cancer patients who underwent gastric resection at the Department of Gastrointestinal Surgery of Wuhan University Renmin Hospital.
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Nat Med
January 2025
Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), University of Vic - Central University of Catalonia, Barcelona, Spain.
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC.
View Article and Find Full Text PDFDiagnostic performance and clinical outcomes of computed tomography colonography in a sick inpatient population.
Clin Imaging
January 2025
NYU Langone Health, Department of Radiology, 660 1st Ave, New York, NY 10016, United States.
Purpose: Though prior studies have proven CTC's efficacy in outpatients, its utility in the inpatient setting has not been studied. We evaluated the efficacy of a modified CTC protocol in the inpatient setting, primarily for patients awaiting organ transplantation.
Methods: This retrospective study compared a group of inpatient CTCs from 2019 to 2021 and a randomly selected, age-matched 2:1 control group of outpatient CTCs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!